84235-34-7

Basic information

• Product Name: endo-2-aminonorbornane
• Synonyms: endo-2-aminonorbornane
• CAS NO: 84235-34-7
• Molecular Weight: 111.187
• Mol File: 84235-34-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: endo-2-aminonorbornane(CAS DataBase Reference)
• NIST Chemistry Reference: endo-2-aminonorbornane(84235-34-7)
• EPA Substance Registry System: endo-2-aminonorbornane(84235-34-7)

Safety Data

• Hazardous Substances Data: 84235-34-7(Hazardous Substances Data)

Upstream product

• 342029-20-3 C₇H₁₁BrZn 
• 498-66-8 norborn-2-ene 
• 14370-45-7 (±)-endo-2-norbornylamine hydrochloride 
• 4576-48-1 bicyclo[2.2.1]heptan-2-one oxime 
• 497-38-1 2-norbornanone 
• 72203-34-0 norbornene-2-carboxylate methyl ester 
• 1389327-48-3 N-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-yl)-4-(trifluoromethyl)benzamide 

Downstream Products

• 497-37-0 exo-2-norbornanol 
• 1226884-40-7 N₄-((2R)-bicyclo[2.2.1]heptan-2-yl)-6-methyl-N₂-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4-diamine 

Relevant articles and documents

Potential Synthetic Adaptogens: V. Synthesis of Cage Monoamines by the Schwenk–Papa Reaction

The reduction of cage ketoximes under Schwenk–Papa reaction conditions was studied to establish that the d,l, d- and l-camphor oximes are smoothly reduced to the corresponding amines in high yields. At the same time, d,l-norcamphor and adamantan-2-one oximes undergo partial catalytic deoximation to form a mixture of the corresponding amines and alcohols.

Iridium-catalyzed intermolecular hydroamination of unactivated aliphatic alkenes with amides and sulfonamides

The intermolecular addition of N-H bonds to unactivated alkenes remains a challenging, but desirable, strategy for the synthesis of N-alkylamines. We report the intermolecular amination of unactivated α-olefins and bicycloalkenes with arylamides and sulfonamides to generate synthetically useful protected amine products in high yield. Mechanistic studies on this rare catalytic reaction revealed a resting state that is the product of N-H bond oxidative addition and coordination of the amide. Rapid, reversible dissociation of the amide precedes reaction with the alkene, but an intramolecular, kinetically significant rearrangement of the species occurs before this reaction with alkene.

ISOXAZOLES AND THEIR USE IN THE TREATMENT OF ISCHEMIC DISEASES

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof. These compounds are useful for the treatment of neurological, neurodegenerative, ischemic and inflammatory disorders. Accordingly, the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of neurological, neurodegenerative, ischemic and inflammatory disorders.